Understanding retinal blood vessel changes in Fabry disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore endothelial dysfunction in patients with Fabry disease by analyzing the retinal microvasculature. It will assess both dynamic and static parameters of retinal vessels to determine how they differ from healthy individuals and whether they can predict cardiovascular events related to Fabry disease. The study will utilize non-invasive techniques such as dynamic retinal vessel analysis, optical coherence tomography, and patient-reported outcomes to gather comprehensive data on disease severity and cardiovascular risk. The findings may help in monitoring the effectiveness of enzyme replacement therapy and improving patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18 years
* Diagnosis of Fabry disease by genetic testing or GB3 activity in leukocytes.
* Signed informed consent form

Exclusion Criteria:

* Active infection or cancer
* Surgery less than 2 weeks prior to inclusion in the study
* Known glaucoma
* Lack of capacity to give consent; lack of informed consent.
* Known epilepsy

Where it's running

• Department of nephrology, Klinikum rechts der Isar
  München, Bavaria, Germany Recruiting

Study contacts

• Principal investigator: Roman Günthner, PD Dr. — Abteilung für Nephrologie
• Study coordinator: Christoph Schmaderer, Prof. Dr.
• Email: christoph.schmaderer@mri.tum.de
• Phone: 089 4140 5053

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lucerastat in untreated adult men with Fabry disease shows how well it works and safety

  This study tests lucerastat to see if it can reduce Gb3 buildup and be safe in untreated adult men with Fabry disease.

  Recruiting Phase 3 Idorsia Pharmaceuticals Ltd. · Birmingham, Alabama and 15 other locations · NCT07778667

• Endothelial extracellular vesicles in kids with newly diagnosed high blood pressure

  This study tests whether levels of endothelial extracellular vesicles are different in children with new, untreated primary hypertension compared to normotensive children.

  Recruiting Josip Juraj Strossmayer University of Osijek · Osijek · NCT07728643

• Periodontal Health in Rare Kidney Conditions and Controls

  This study tests how common periodontitis is in people with rare kidney disorders and compares it to CKD patients and people without kidney disease.

  Recruiting Institutul Clinic Fundeni · Bucharest · NCT07575347

• Anderson-Fabry disease fitness improvement program

  This study tests whether a 12-week physiotherapy-led exercise program can improve function, fitness, strength, and quality of life in adults with Fabry disease.

  Recruiting General University Hospital, Prague · Prague · NCT07495410

• TB-500 (thymosin beta 4 fragment) to improve blood vessel function in people with stable atherosclerotic cardiovascular disease

  This trial will test whether TB-500 (a fragment of thymosin beta 4) is safe and can improve blood vessel function in adults aged 40–75 with stable ASCVD.

  Recruiting Phase 1/2 Hudson Biotech · Shenzhen, Guangdong · NCT07487363

• Statin effects on hormones and erectile function in middle-aged men

  This will test whether different doses of pitavastatin or rosuvastatin change sex hormone levels and improve erectile function in sexually active men aged 40-65 with high cardiovascular risk.

  Recruiting Phase 2 Lomonosov Moscow State University Medical Research and Educational Center · Moscow · NCT07460960

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.